Figure 4From: JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patientsMemory/Naïve T lymphocyte subsets. Relative proportions of VP-1 stimulated CD8+naïve (CCR7+CD45RA+), central memory (CM: CCR7+CD45RA-), effector memory (EM: CCR7-CD45RA-), and terminally differentiated (TD: CCR7-CD45RA+) T lymphocytes in Multiple Sclerosis patients undergoing natalizumab. Samples were tested at baseline (PRE), at the time of JCV DNA isolation in blood (POS), and after 24 months of therapy (POST).Back to article page